Aradigm Corporation (ARDM): Product News News

ARDM – FDA Advisory Committee did not recommend approval for Linhaliq as treatment for non-cystic fibrosis bronchiectasis patients with chronic lung Pseudomonas aeruginosa infections.


Key Facts Surrounding This News Item


  • ARDM had a POWR Rating of C (Neutral) coming into today.
  • ARDM was -40.68% below its 10-Day Moving Average coming into today.
  • ARDM was -38.54% below its 20-Day Moving Average coming into today.
  • ARDM was -24.34% below its 50-Day Moving Average coming into today.
  • ARDM was -7.19% below its 100-Day Moving Average coming into today.
  • ARDM was 36.12% above its 200-Day Moving Average coming into today.
  • ARDM had returned -48.96% year-to-date leading up to today’s news, versus a +2.72% return from the benchmark S&P 500 during the same period.

More Info About Aradigm Corporation (ARDM)


Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. The company was founded in 1991 and is based in Hayward, California. View our full ARDM ticker page with ratings, news, and more.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

ARDM at a Glance

ARDM Current POWR Rating™
Overall POWR Rating™
ARDM Current Price $1.21 7.63%
More ARDM Ratings, Data, and News

ARDM Price Reaction

The day of this event (Jan. 11, 2018)
ARDM Closing Price0.00 N/A%
ARDM Volume0
N/A% from avg
Leading up to this event
ARDM 1-mo return26.92%

ARDM Price Chart



More Aradigm Corporation (ARDM) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ARDM News
Page generated in 2.1605 seconds.